Pharmaceutical - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

1 to 25 of 7103 results

EMA calls for strengthened warnings for Iclusig

24-10-2014

The European Medicines Agency has concluded its review of the benefits and risks of Iclusig (ponatinib),…

Ariad PharmaceuticalsEuropeIclusigOncologyPharmaceuticalRegulation

Shire posts sharp rises in sales and earnings for third-qtr

24-10-2014

Ireland-headquartered Shire has delivered a strong set of financials for the third-quarter of 2014, validating…

AbbVieFinancialPharmaceuticalShire

AstraZeneca’s Lynparza backed for approval by EMA committee

24-10-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

AstraZenecaEuropeLynparzaolaparibOncologyPharmaceuticalRegulation

EMA completes review of polymyxins and issues updated guidance

EMA completes review of polymyxins and issues updated guidance

24-10-2014

The European Medicines Agency has completed its review of polymyxin-based medicines and issued its recommendations…

Antibiotics and Infectious diseasesColistimethateEuropePharmaceuticalRegulation

VIDEO: Chief executive Sir Andrew Witty discusses GSK's results

VIDEO: Chief executive Sir Andrew Witty discusses GSK's results

24-10-2014

Chief executive of UK pharma giant GlaxoSmithKline Sir Andrew Witty has commented on the company's third…

FinancialGlaxoSmithKlinePharmaceuticalPharmaceutical industryUK

Australian government to undertake review of medicines and medical devices regulation

Australian government to undertake review of medicines and medical devices regulation

24-10-2014

The Australian government is to carry out a review of the regulation of medicines and medical devices.

AustraliaMedicineMedicines AustraliaPharmaceuticalRegulation

Singapore reports sharp downturn in biomedical manufacturing for September

24-10-2014

On a year-on-year basis, Singapore’s manufacturing output contracted 1.2% in September 2014, mainly…

PharmaceuticalSingapore

Experts' comments on GSK floating its HIV business

24-10-2014

The announcement this week by UK pharma giant GlaxoSmithKline that it is mulling a possible initial public…

FinancialGlaxoSmithKlinePharmaceuticalViiV Healthcare

The cancer drug discovery system is broken, global summit hears

The cancer drug discovery system is broken, global summit hears

24-10-2014

Here's our take on the week's top stories.

CancerOncologyPharmaceuticalResearchUK

Vaxart accelerates development of Ebola tablet vaccine

24-10-2014

Privately-held US vaccine developer Vaxart says it is accelerating its Ebola tablet vaccine program.…

Anti-viralsPharmaceuticalResearchVaccinesVaxart

Genmab gets latest milestone in daratumumab Janssen collaboration

Genmab gets latest milestone in daratumumab Janssen collaboration

24-10-2014

Danish biotech company Genmab has reached the fourth milestone in its daratumumab collaboration with…

daratumumabDenmarkGenmabJanssenOncologyPharmaceuticalResearch

Acute pain market to grow less than 0.5% between 2013 and 2023, says new research

Acute pain market to grow less than 0.5% between 2013 and 2023, says new research

24-10-2014

The acute pain market will experience only minimal growth between 2013 and 2023, according to biopharma…

AnalgesiaCelebrexDecision Resources GroupMarkets & MarketingPharmaceutical

Stallergenes furthers global expansion and opens affiliate in Ontario, Canada

Stallergenes furthers global expansion and opens affiliate in Ontario, Canada

24-10-2014

Stallergenes, a France-based global healthcare company specialized in diagnosis and treatment of allergies,…

CanadaMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenes

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

23-10-2014

US drug major Eli Lilly reported third quarter 2014 results that showed how badly the company has been…

CymbaltaEli LillyEli Lilly and CompanyEvistaFinancialPharmaceuticalUnited StatesUSA

Takeda gains exclusive rights to Amitiza beyond US and Canada

Takeda gains exclusive rights to Amitiza beyond US and Canada

23-10-2014

US biopharma company Sucampo Pharmaceuticals saw its shares rise 5.6% to $8.46 in morning trading, after…

AmitizaGastro-intestinalsGlobalLicensingPharmaceuticalSucampoTakeda Pharmaceutical

Lilly expands collaboration with Zymeworks

Lilly expands collaboration with Zymeworks

23-10-2014

US pharma major Eli Lilly and privately-held Canadian biotech firm Zymeworks have expanded their existing…

CanadaEli LillyLicensingOncologyPharmaceuticalResearchUSAZymeworks

Ferring Pharma’s Cortiment gains EU approval

Ferring Pharma’s Cortiment gains EU approval

23-10-2014

Privately-held Switzerland-headquartered Ferring Pharmaceuticals says its Cortiment (budesonide) treatment…

CortimentCosmo PharmaceuticalsEuropeFerring PharmaceuticalsGastro-intestinalsPentasaPharmaceuticalRegulation

EMA moves further to push Ebola treatments development

EMA moves further to push Ebola treatments development

23-10-2014

During the past months, the European Medicines Agency has put in place a system to give the best possible…

Anti-viralsEuropePharmaceuticalRegulationResearchVaccines

Cost of Australian PBS rises below rate of inflation for 2013-2014

Cost of Australian PBS rises below rate of inflation for 2013-2014

23-10-2014

The Australian Department of Health has confirmed that growth of the Pharmaceutical Benefits Scheme cost…

AustraliaMedicines AustraliaPharmaceuticalPharmaceuticals policyRegulation

Partnership led by UK Medical Research Council to invest more than $368 million in medical technology

Partnership led by UK Medical Research Council to invest more than $368 million in medical technology

23-10-2014

The UK’s chancellor of the exchequer, George Osborne, has announced that a partnership led by the Medical…

PharmaceuticalResearchUKUnited KingdomWELLCOME TRUST

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

Abbott raises midpoint of EPS guidance and sees shares rise as quarterly profit exceeds forecast

Abbott raises midpoint of EPS guidance and sees shares rise as quarterly profit exceeds forecast

22-10-2014

Shares of US health care company Abbott Laboratories rose slightly in the premarket trading period following…

Abbott LaboratoriesFinancialPharmaceuticalUnited StatesUSA

1 to 25 of 7103 results

Back to top